Spago Nanomedical
0.12 SEK
Less than 1K followers
SPAGO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-2.48 %
-9.92 %
+1.29 %
+6.31 %
-40.73 %
-12.34 %
-79.24 %
-97.67 %
-98.54 %
Spago Nanomedical is active in biotechnology. The company develops nanomedicine for the diagnosis and treatment of life-threatening diseases. The company's main activities are focused on developing a cancer-selective contrast agent for magnetic resonance imaging (MRI), as well as a product for radionuclide treatment of cancer. Both of these projects are based on proprietary nanomaterials. The largest operations are in the Nordic market, with the headquarters located in Lund.
Read moreMarket cap
78.07M SEK
Turnover
-
Revenue
437K
EBIT %
-6,165.68 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
7/5
2026
Interim report Q1'26
10/6
2026
General meeting '26
20/8
2026
Interim report Q2'26
All
Press releases
3rd party
ShowingAll content types
Spago Nanomedical bokslutskommuniké januari-december 2025
Spago Nanomedical year-end report January-December, 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools